Haemonetics Corporation disclosed that director Martin D. Madaus acquired 2,538 restricted stock units on July 24, 2026, as part of the company's equity compensation program. The RSUs, which vest over one year, represent a standard component of board compensation at the Boston-based medical device manufacturer. The disclosure was filed with the SEC on July 28, 2026, and provides investors with transparency into executive and director equity holdings at the company.
Key Points
- NYSE: HAE
- Director Martin D. Madaus received 2,538 restricted stock units on July 24, 2026
- RSUs vest 100 percent on the first anniversary of the grant date; each unit converts to one share of common stock upon vesting
- Grant was issued under the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan
RSU Grant Details and Vesting Schedule
Martin D. Madaus, who serves as a director of Haemonetics Corporation, received 2,538 restricted stock units on July 24, 2026, according to the company's disclosure. The RSUs were awarded under the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan, the framework through which the company structures equity compensation for its board members and executives. Each RSU represents a contingent right to receive one share of Haemonetics common stock when the unit vests.
The vesting structure for this grant is straightforward: 100 percent of the RSUs vest on the first anniversary of the grant date, meaning the entire position will convert to common stock on July 24, 2027. This one-year cliff vesting approach is a common practice among public companies for director equity compensation, aligning board members' interests with shareholder value over a defined timeframe. Following the reported transaction, Madaus holds 2,538 RSUs directly, with ownership classified as direct rather than indirect.
Director Status and Board Participation
Martin D. Madaus holds the position of director at Haemonetics, as indicated by the checkbox marked on the ownership disclosure form. The filing does not indicate that Madaus holds any other officer titles or positions within the company, nor does it disclose that he is a beneficial owner of 10 percent or more of the company's outstanding shares. His role as a director places him among the governance body responsible for overseeing Haemonetics' strategic direction, financial performance, and compliance matters.
Director compensation at public companies typically includes both cash and equity-based elements. The grant of RSUs to Madaus represents the equity component of board compensation, designed to create ongoing alignment between director interests and those of Haemonetics shareholders. The timing of the award on July 24, 2026, falls within the company's standard compensation cycle, though the specific circumstances or purpose of this particular grant were not detailed in the regulatory filing.
Haemonetics' Equity Compensation Framework
Haemonetics Corporation administers equity compensation through its Amended and Restated 2019 Long-Term Incentive Compensation Plan, which serves as the umbrella framework for grants to employees, officers, and directors. This plan structure allows the company to award various types of equity securities, including restricted stock units, stock options, and other incentive vehicles. The use of RSUs in particular has become standard practice in corporate America, as they provide clear economic exposure to stock price movements without requiring participants to exercise options or purchase shares upfront.
The 2019 plan, as amended and restated, reflects Haemonetics' approach to talent retention and incentive alignment across its organization. By concentrating equity grants under a single plan approved by shareholders, the company maintains governance discipline and transparency regarding total equity dilution and compensation expense. The specific use of one-year cliff vesting for director grants suggests Haemonetics follows a measured approach to board compensation, with annual review and refresh cycles rather than perpetual rolling grants.
Boston-Based Medical Device Company Overview
Haemonetics Corporation, headquartered at 125 Summer Street in Boston, Massachusetts, is a publicly traded medical device company listed on the New York Stock Exchange under the ticker HAE. The company operates in the healthcare sector, where equity compensation and board engagement are critical components of governance and talent management. As with other publicly traded healthcare companies, Haemonetics is subject to SEC reporting requirements that mandate disclosure of all insider trading and equity transactions involving officers, directors, and major shareholders.
The company's Boston location places it within one of the United States' leading healthcare and life sciences clusters, an area with substantial concentration of medical device, pharmaceutical, and healthcare services companies. This geographic positioning has historically provided Haemonetics with access to specialized talent, research institutions, and industry expertise relevant to its operations and strategic objectives.
Regulatory Filing and Disclosure Compliance
The disclosure of Madaus's RSU acquisition was filed on July 28, 2026, four days after the grant date of July 24, 2026. This filing complies with Section 16(a) of the Securities Exchange Act of 1934, which requires officers, directors, and 10 percent beneficial owners to report changes in their beneficial ownership of company securities. The form was executed by Thomas V. Powers, identified as attorney-in-fact for Dr. Madaus, indicating that the filing was prepared and submitted on behalf of the director through a designated representative.
The SEC's Form 4 requirement serves to provide transparency to investors regarding insider equity transactions and holdings. By publicly disclosing these transactions within the required timeframe, the company and its insiders demonstrate compliance with securities laws designed to prevent information asymmetries and insider trading. All such filings are made available on the SEC's EDGAR database, allowing investors, analysts, and researchers to track insider activity across all publicly traded companies.
Nature of Restricted Stock Units as Compensation
Restricted stock units function as a form of deferred equity compensation that obligates the company to transfer shares to the recipient upon satisfaction of vesting conditions, typically the passage of time. Unlike stock options, which require an exercise price and represent contingent rights to purchase shares, RSUs provide direct exposure to share price appreciation from the grant date forward, even though the recipient does not hold actual shares until vesting occurs. From an accounting and valuation perspective, RSUs are typically valued based on the fair market value of the underlying stock on the grant date.
For board members and executives, RSUs serve multiple objectives: they align compensation with shareholder returns, encourage long-term retention, and create a direct financial stake in the company's performance. The one-year cliff vesting structure typical of Haemonetics' director grants means that the full economic benefit accrues only after a 12-month period, reinforcing the expectation of continued board service and engagement throughout that period. Upon vesting, RSUs convert automatically to common shares without requiring further action from the recipient.
Beneficial Ownership Tracking and Investor Significance
The disclosure indicates that following the reported transaction, Madaus beneficially owns 2,538 shares or RSU equivalents on a direct basis. Beneficial ownership is tracked both for governance purposes and to monitor potential conflicts of interest or informational advantages held by insiders. For investors evaluating Haemonetics, tracking insider equity transactions and holdings can provide signals regarding management confidence in the company's prospects, compensation practices, and governance standards.
However, a single grant of director compensation, standing alone, typically does not provide significant predictive information about company performance or strategic direction. Rather, patterns of insider buying, selling, or grant activity viewed over time may offer more meaningful insights. Investors monitoring Haemonetics should consider director and officer transactions as one component of a broader due diligence process that includes analysis of financial performance, competitive positioning, and strategic initiatives.
Standard Practice in Healthcare Board Governance
Director equity grants such as the one awarded to Madaus reflect standard governance practices in the healthcare and medical device sectors. Public company boards typically receive a mix of annual cash retainers, meeting fees, and equity awards intended to align director interests with shareholder value creation. The equity component ensures that directors participate directly in stock price movements, creating incentive alignment on matters affecting long-term shareholder returns. In the medical device industry specifically, board expertise in regulatory affairs, clinical science, and healthcare economics makes director retention and engagement particularly important.
Haemonetics' use of RSU grants under its 2019 Long-Term Incentive Compensation Plan aligns with practices observed across comparable healthcare and medical technology companies. The one-year vesting schedule provides flexibility for the company to refresh director compensation annually while maintaining clear performance linkage and retention objectives. This approach balances the need to attract and retain qualified directors with shareholder interests in managing dilution and controlling total equity expense.




Please wait processing your request...